Guardant Health, INC Form 4 insider transactions

A director at Guardant Health, Inc. sold 116 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $59.02 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Manuel Hidalgo Medina converted 232 Restricted Stock Units into common stock, increasing his direct common stock holdings to 3,016 shares.

Guardant Health Director Tariq Musa reported a future acquisition of 250 common shares and 250 restricted stock units, stemming from a pre-existing vesting schedule.

Guardant Health Director Myrtle S. Potter acquired 69 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Meghan V. Joyce reported the acquisition of 67 common shares through the vesting of restricted stock units.

Guardant Health Director Steve Krognes acquired 154 shares of common stock via restricted stock unit vesting.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $48.20 per share on July 17, 2025, as part of a Rule 10b5-1 trading plan.

Myrtle S. Potter, a Director at Guardant Health, Inc., has filed a Form 4 indicating a planned sale of 26 shares of common stock on July 17, 2025, under a Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Manuel Hidalgo Medina acquired 2,784 common shares through the vesting of restricted stock units on July 17, 2025, as part of a previously granted equity award.

Guardant Health, Inc. Director Tariq Musa acquired 250 shares of common stock through the exercise of Restricted Stock Units (RSUs) on July 15, 2025, increasing his direct beneficial ownership to 7,440 shares.

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the acquisition of 68 shares of common stock on July 15, 2025, increasing her direct beneficial ownership to 18,222 shares.

Guardant Health, Inc. Director Meghan V. Joyce acquired 66 shares of common stock on July 4, 2025, through the vesting of Restricted Stock Units.

Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and a corresponding disposal of shares to cover tax withholding obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the acquisition of shares through Restricted Stock Unit vesting and the subsequent disposition of shares for tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent share disposition for tax withholding purposes.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and associated tax withholding transactions on July 1, 2025, as detailed in a recent SEC Form 4 filing.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations.

Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported the vesting of restricted stock units and the subsequent disposition of shares to cover tax obligations.

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, reported the acquisition of common stock through RSU vesting and subsequent sales and tax withholdings, primarily executed under a pre-arranged 10b5-1 trading plan.

Guardant Health, Inc. Director Steve E. Krognes has filed a Form 4 detailing the future vesting of 154 common shares from Restricted Stock Units on June 30, 2025.

Guardant Health, Inc. Co-Chief Executive Officer and Director Helmy Eltoukhy reported the vesting of restricted stock units and subsequent tax-related share dispositions in late June and early July 2025.

Guardant Health Director Tariq Musa reported the sale of 3,213 shares of common stock and the acquisition of 6,833 stock options and 4,203 restricted stock units, all executed under a Rule 10b5-1 trading plan.

Myrtle S. Potter, a Director at Guardant Health, Inc., reported the sale of a small number of common shares and the acquisition of substantial stock options and restricted stock units, all executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health, Inc. Director Roberto Mignone was granted 6,833 stock options and 4,203 restricted stock units, aligning his interests with long-term shareholder value.

Guardant Health, Inc. Director Steve E. Krognes was granted 6,833 stock options and 4,203 restricted stock units (RSUs) as part of his compensation.

Guardant Health, Inc. Director Meghan V. Joyce was granted 6,833 stock options and 4,203 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

Guardant Health, Inc. Director Manuel Hidalgo Medina was granted 6,833 stock options and 4,203 restricted stock units on June 18, 2025, as part of his compensation.

Guardant Health, Inc. Director Vijaya Gadde has reported the acquisition of stock options and restricted stock units, granted on June 18, 2025, as part of her compensation.

Guardant Health, Inc. Director Ian T. Clark disclosed the sale of common stock and the acquisition of new stock options and restricted stock units, as part of pre-arranged trading plans.